Sigyn Therapeutics, Inc.
SIGY • Biotechnology
$0.03
— 0.00 (0.00%)
Current price
EarningsLatest report: Mar 31, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$63,522.093
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Weak liquidity · 0.01Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: Mar 31, 2026, 12:00 AM UTCLast profile update: Sep 2, 2026, 12:19 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.03
Change0.00%
Shares Out2.19M
Market Cap$63.52K
Enterprise Value$3.24M
Beta-0.06
P/E-0.02
P/B-0.01
P/FCF-0.10
EV/EBITDA-1.87
EV/FCF-4.96
Dividend Yield0.00%
Price$0.03
Change0.00%
Shares Out2.19M
Market Cap$63.52K
Enterprise Value$3.24M
Beta-0.06
P/E-0.02
P/B-0.01
P/FCF-0.10
EV/EBITDA-1.87
EV/FCF-4.96
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq-0.47
Current Ratio0.01
Quick Ratio0.01
Revenue 5Y-100.00%
Volume80.11K
Avg Volume32.85K
Investment DNA
How strong this company looks for long-term investors
33
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
20/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
50/100
Why this score▼
Weak liquidity · 0.01Weak profitability
Analyst view
No analyst data available now.
🧾
No insider activity
No recent insider transactions available.